Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Fomepizole versus ethanol in the treatment of acute methanol poisoning: Comparison of clinical effectiveness in a mass poisoning outbreak

S. Zakharov, D. Pelclova, T. Navratil, J. Belacek, M. Komarc, M. Eddleston, KE. Hovda,

. 2015 ; 53 (8) : 797-806. [pub] 20150624

Language English Country England, Great Britain

Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

CONTEXT: Mass or cluster methanol poisonings are frequently reported from around the world. The comparative effectiveness of ethanol and fomepizole as antidotes for methanol poisoning is unknown due to the difficulty of performing a randomized controlled trial. OBJECTIVE: During an outbreak of mass poisonings in the Czech Republic in 2012-2014, we compared the effects of antidotes on the frequency of health sequelae and mortality. METHODS: The study was designed as a cross-sectional case series and quasi-case-control study. Patients with a diagnosis of methanol poisoning on admission to hospitals were identified for the study. Diagnosis was established when (i) a history of recent ingestion of illicit spirits was available and serum methanol was higher than 6.2 mmol/L (20 mg/dL), or (ii) there was a history/clinical suspicion of methanol poisoning, and serum methanol was above the limit of detection with at least two of the following: pH < 7.3, serum bicarbonate < 20 mmol/L, and anion gap or AG ≥ 20 mmol/L. Fomepizole was given as a bolus dose of 15 mg/kg i.v. diluted in isotonic saline, followed by 10 mg/kg every 12 h (every 4 h during hemodialysis); ethanol was administered both intravenously as a 10% solution in 5% glucose, and per os in boluses of 20% solution. Multivariate regression was applied to determine the effect of antidote on outcome. Additionally, for a retrospective quasi-case-control study, a control group of patients treated with ethanol, matched carefully on severity of poisoning and other key parameters, was selected. RESULTS: Data were obtained from 100 hospitalized patients with confirmed poisoning: 25 patients treated with fomepizole were compared with 68 patients receiving ethanol (seven patients did not receive any antidote). More severely acidotic (p < 0.001) and late-presenting (>12 h; p = 0.028) patients received fomepizole more often than ethanol, as reflected in the higher number of fomepizole-treated patients being intubated (p = 0.009). No association was found between the type of antidote and the survival in either the case series (p = 0.205) or the quasi-control groups (p = 0.705) in which patients were very closely matched to minimize confounding by allocation. In the multivariate analysis, positive serum ethanol (odds ratio [OR], 10.8; 95% confidence interval [CI], 2.9-39.9) and arterial blood pH (OR, 3.7; 95% CI, 1.3-10.5) on admission were the only independent variables for the survival. The median intensive care unit length of stay was 6 (range, 2-22) days in the fomepizole group and 4 (range, 1-33) days in the ethanol group (p = 0.131). There were no differences in the use of elimination techniques between the two groups (neither in the full material (n = 100), nor the case-control groups (n = 50)). CONCLUSIONS: This study on antidotes for methanol poisoning did not show any evidence of different clinical effectiveness. Although ethanol is generally associated with a higher incidence of complications, this study suggests that both antidotes are similarly effective and that ethanol should not be avoided on grounds of effectiveness.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000106
003      
CZ-PrNML
005      
20160122125447.0
007      
ta
008      
160108s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.3109/15563650.2015.1059946 $2 doi
035    __
$a (PubMed)26109326
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Zakharov, Sergey $u Department of Occupational Medicine, Toxicological Information Center, First Faculty of Medicine, Charles University in Prague and General University Hospital , Na Bojisti, Prague , Czech Republic.
245    10
$a Fomepizole versus ethanol in the treatment of acute methanol poisoning: Comparison of clinical effectiveness in a mass poisoning outbreak / $c S. Zakharov, D. Pelclova, T. Navratil, J. Belacek, M. Komarc, M. Eddleston, KE. Hovda,
520    9_
$a CONTEXT: Mass or cluster methanol poisonings are frequently reported from around the world. The comparative effectiveness of ethanol and fomepizole as antidotes for methanol poisoning is unknown due to the difficulty of performing a randomized controlled trial. OBJECTIVE: During an outbreak of mass poisonings in the Czech Republic in 2012-2014, we compared the effects of antidotes on the frequency of health sequelae and mortality. METHODS: The study was designed as a cross-sectional case series and quasi-case-control study. Patients with a diagnosis of methanol poisoning on admission to hospitals were identified for the study. Diagnosis was established when (i) a history of recent ingestion of illicit spirits was available and serum methanol was higher than 6.2 mmol/L (20 mg/dL), or (ii) there was a history/clinical suspicion of methanol poisoning, and serum methanol was above the limit of detection with at least two of the following: pH < 7.3, serum bicarbonate < 20 mmol/L, and anion gap or AG ≥ 20 mmol/L. Fomepizole was given as a bolus dose of 15 mg/kg i.v. diluted in isotonic saline, followed by 10 mg/kg every 12 h (every 4 h during hemodialysis); ethanol was administered both intravenously as a 10% solution in 5% glucose, and per os in boluses of 20% solution. Multivariate regression was applied to determine the effect of antidote on outcome. Additionally, for a retrospective quasi-case-control study, a control group of patients treated with ethanol, matched carefully on severity of poisoning and other key parameters, was selected. RESULTS: Data were obtained from 100 hospitalized patients with confirmed poisoning: 25 patients treated with fomepizole were compared with 68 patients receiving ethanol (seven patients did not receive any antidote). More severely acidotic (p < 0.001) and late-presenting (>12 h; p = 0.028) patients received fomepizole more often than ethanol, as reflected in the higher number of fomepizole-treated patients being intubated (p = 0.009). No association was found between the type of antidote and the survival in either the case series (p = 0.205) or the quasi-control groups (p = 0.705) in which patients were very closely matched to minimize confounding by allocation. In the multivariate analysis, positive serum ethanol (odds ratio [OR], 10.8; 95% confidence interval [CI], 2.9-39.9) and arterial blood pH (OR, 3.7; 95% CI, 1.3-10.5) on admission were the only independent variables for the survival. The median intensive care unit length of stay was 6 (range, 2-22) days in the fomepizole group and 4 (range, 1-33) days in the ethanol group (p = 0.131). There were no differences in the use of elimination techniques between the two groups (neither in the full material (n = 100), nor the case-control groups (n = 50)). CONCLUSIONS: This study on antidotes for methanol poisoning did not show any evidence of different clinical effectiveness. Although ethanol is generally associated with a higher incidence of complications, this study suggests that both antidotes are similarly effective and that ethanol should not be avoided on grounds of effectiveness.
650    _2
$a intravenózní podání $7 D061605
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antidota $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000931
650    _2
$a rozdělení chí kvadrát $7 D016009
650    _2
$a průřezové studie $7 D003430
650    12
$a epidemický výskyt choroby $7 D004196
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ethanol $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000431
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hospitalizace $7 D006760
650    _2
$a lidé $7 D006801
650    _2
$a jednotky intenzivní péče $7 D007362
650    _2
$a délka pobytu $7 D007902
650    _2
$a lineární modely $7 D016014
650    _2
$a logistické modely $7 D016015
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methanol $x otrava $7 D000432
650    _2
$a lidé středního věku $7 D008875
650    _2
$a multivariační analýza $7 D015999
650    _2
$a otrava $x diagnóza $x farmakoterapie $x mortalita $7 D011041
650    _2
$a pyrazoly $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D011720
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pelclova, Daniela
700    1_
$a Navratil, Tomas
700    1_
$a Belacek, Jaromir
700    1_
$a Komarc, Martin
700    1_
$a Eddleston, Michael
700    1_
$a Hovda, Knut Erik
773    0_
$w MED00013938 $t Clinical toxicology (Philadelphia, Pa.) $x 1556-9519 $g Roč. 53, č. 8 (2015), s. 797-806
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26109326 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20160122125607 $b ABA008
999    __
$a ok $b bmc $g 1102387 $s 924312
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 53 $c 8 $d 797-806 $e 20150624 $i 1556-9519 $m Clinical toxicology $n Clin Toxicol (Phila) $x MED00013938
LZP    __
$a Pubmed-20160108

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...